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Background: Spinal muscular atrophy is a rare genetic disease, which primarily 
affects motor neurons and predominantly occurs in children. To date, alternatives 
for the treatment of the disease have been controversial. Spinal muscular atrophy 
has a multi-factorial aetiology, with mitochondrial oxidative stress considered as 
the crucial pathogenic mechanism. To determine the mechanisms underlying the 
loss of motor neurons, NSC-34 motor neuron-like cells are often used as an in vitro 
model of spinal muscular atrophy. As plastin 3 (PLS3) has been demonstrated as 
a modifier of spinal muscular atrophy, the aim of the current study was to evaluate 
the neuroprotective effect of PLS3 in NSC-34 cells. 
Materials and methods: Plastin 3 was overexpressed in human embryonic kidney 
293T cells and NSC-34 cells via lentiviral transduction. NSC-34 cells transduced with 
a lentiviral vector carrying the gene for LacZ β-galactosidase served as a control. 
Oxidative stress was then induced by depriving cells of serum, and the protective 
effect of PLS3 was assessed using a cellular reactive oxygen species detection assay. 
Results: While PLS3 was successfully overexpressed in human embryonic kidney 
293T cells and NSC-34 cells, upregulation of this protein did not significantly 
decrease oxidative stress in serum-deprived NSC-34 cells relative to controls. 
Conclusions: Plastin 3 overexpression in NSC-34 cells did not elicit an antioxidative 
effect following serum deprivation. (Folia Morphol 2019; 78, 1: 1–9)
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INTRODUCTION
Spinal muscular atrophy (SMA) — a destructive 
motor neuron (MN) disorder which occurs in infancy 
— is primarily caused by survival motor neuron 1 gene 
(SMN1) mutations. SMN1 and SMN2 are nearly iden-
tical genes encoding the survival motor neuron (SMN) 
protein [16, 23]. Mutations in the SMN1 gene lead 
to the reduction or loss of SMN protein expression, 
causing motor axon defects and MN death [3, 16]. 
Generally, reduced SMN protein expression is be-
lieved to cause the death of lower motor neurons, 
thereby inducing denervation and skeletal muscle 
atrophy [3]. The major clinical characteristic of SMA 
is the selective and progressive loss of MNs via ap-
optosis, although the factors, which trigger this loss, 
remain unknown [9]. Multiple interacting factors have 
been implicated in MN lesions, including mitochondri-
al dysfunction, excitotoxicity, protein aggregation and 
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misfolding, defective axonal transport, dysregulated 
transcription and RNA processing, apoptosis, and 
oxidative stress [5, 16, 17]. 
While SMA has traditionally been classified as 
a pure lower MN disease, it is becoming clear that 
supplementary cells and tissue types are particularly 
susceptible to decreased SMN expression. Current ther-
apeutic strategies focus on increasing SMN expression; 
however, developing an effective treatment for all 
affected cells remains a challenge. Targeting cells other 
than MNs in order to successfully provide therapy for 
SMA is possible via the intramuscular administration 
of adeno-associated virus serotype 9 (AAV9) carrying 
the SMN gene, which can enter the spinal cord via 
retrograde transport and transduce multiple organs in 
peripheral tissues. Indeed, gene therapy approaches 
using AAV9-SMN vectors have entered phase I clinical 
trials and are highly promising. However, limitations 
associated with this treatment highlight the need for 
combined therapies that rescue both MN function and 
increase SMN levels. As such, the identification and 
characterisation of SMA-related pathologies that occur 
across tissues and affected cells is crucial for the devel-
opment of novel SMA therapeutic strategies [2, 16].
Oxidative stress is an instrumental factor in the 
pathogenesis of many neurodegenerative diseases 
[14], and typically occurs when a cell fails to cope 
with excess levels of reactive oxygen species (ROS), 
resulting in toxic effects facilitated by peroxides and 
free radicals. ROS is formed via uncoupled nitric ox-
ide synthase and nicotinamide adenine dinucleotide 
phosphate oxidase [26]. Antioxidants are important 
for the removal of ROS before they become prob-
lematic. If ROS is not removed, chronic oxidative 
stress can lead to DNA damage and the subsequent 
promotion of cell death [26].
The involvement of oxidative stress in SMA patho-
genesis remains unclear. For instance, nicotinamide 
adenine dinucleotide phosphate levels are reportedly 
elevated in the cardiac tissue of (SMNΔ7) mice, but 
are unchanged in the spinal cord [27]. Moreover, se-
vere mitochondrial oxidative stress is elicited by SMN 
breakdown in human embryonic stem cell-derived MN 
progenitors, and antioxidant treatment with N-ace-
tylcysteine prevents the apoptotic death of MNs [2].
Oprea et al. [23] reported plastin 3 (PLS3), as 
an SMA modifier, qualifying it as a promising ther-
apeutic target. In agreement with this, PLS3 gene 
overexpression has been shown to refine axonal 
outgrowth in SMN-deficient MNs in a zebrafish 
model of SMA as well as in MNs cultured from 
mouse embryos [16, 17]. Several studies have re-
ported an actin-independent role of PLS3 in SMA 
modification [1, 17]; however, investigations on the 
potential protective role of PLS3 against oxidative 
stress have not been performed. Some reports have 
described the involvement of oxidative damage in 
the neurodegenerative process of SMA, and neuro-
protection is considered to be an effective treatment 
option for many central nervous system disorders, 
including neurodegenerative diseases such as SMA 
[5, 17]. Therefore, a therapeutic strategy involving 
antioxidant gene delivery could provide significant 
protection for MNs in SMA [16]. This study is, to the 
best of our knowledge, the first to address whether 
overexpression of PLS3 using a lentiviral vector (LV) 
in an in vitro model of SMA could reduce oxidative 
stress and thus protect MN-like cells. 
MATERIALS AND METHODS
Cell culture
A hybrid mouse MN-neuroblastoma cell line, NSC-34, 
was purchased from Cedarlane Laboratories (CLU 
140-A; thru Tebu-Bio, Le Perray en Yvelines, France) 
and cultured as previously reported [19]. The human 
embryonic kidney cell line, HEK293T, (293T ATCC 
CRL-3216) was also used. All cell lines were cultured 
in tissue culture flasks (CELLSTAR, Greiner, Germany) 
in Dulbecco’s Modified Eagle’s Medium (Lonza, 
BE12-741F) with 10% heat-inactivated foetal bovine 
serum (Biosera, FB-1001), 100 U/mL of penicillin and 
100 μg/mL streptomycin (Invitrogen, Paisley, UK). Cells 
were incubated at 37°C and in 5% CO2 with a 95% 
humidified air atmosphere. Cells were subcultivated 
at a ratio of 1:8 twice weekly by removing medium, 
adding 2 mL of trypsin (Sigma, 9002-07-7) supple-
mented with 0.5 mM ethylenediaminetetraacetic acid 
(EDTA, Sigma, 6381-92-6) in phosphate-buffered sa-
line (PBS), and incubating for several minutes. When 
cells detached, the enzymatic activity of trypsin was 
halted by adding excess culturing medium. All exper-
iments were performed on passage 15–20. Once cells 
reached approximately 80% confluency, they were 
either harvested or left for passaging.
Lentiviral vectors
All LVs were provided by Prof. Mimoun Azzouz at 
the University of Sheffield, United Kingdom and were 
generated in his laboratory. LVs expressing PLS3 were 
constructed by extracting PLS3 gene out of the vector 
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(-pƈ DNA3.1-PLS3-V5-His6) and then cloned it into the 
(SIN-PGK-cPPT-GDNF-WHV) LV; LV titre was 2.55 × 108 
TU/mL. The LV expressing LacZ was generated using 
cDNA for “beta-galactosidase (LacZ)” and “humanistic 
GDNF encompassing Kozak sequence (636 bp frag-
ment, position 1-4851 and 1-151)” (GenBank L19062 
and L19063 accession numbers), thus preventing 
secretion of the trophic factor [11]. These cDNAs 
were replicated in the SIN-W-PGK transfer vector [12].
Transduction of HEK293T and NSC-34 cells with 
LV-PLS3
HEK239T and NSC-34 cells were plated in a 6-well 
plate at a density of 150,000–250,000 cells/well in 
2 mL of medium and incubated overnight at 37°C in 
a CO2 incubator. The LV volume required for trans-
duction was calculated and cells were transduced at 
multiplicity of infection (MOI) of 5, 20, and 40. The 
calculated LV volume was added to each well after the 
removal of 1 mL of medium. After 6 h of incubation, 
wells were supplemented with 1 mL of medium and 
incubated for an additional 3–5 days. 
Five days post-transduction, cells were harvested 
for protein analysis. Non-transduced (NT) cells served 
as a negative control, and an antibody specific for 
human PLS3 protein was used. Protein extraction 
was accomplished by the addition of cell lysis solu-
tion (RIPA buffer) containing 50 mM Tris-HCl pH 8, 
150 mM NaCl, 2 mM EDTA, 1% Igepal CA630 (Sig-
ma), and 0.1% sodium dodecyl sulphate (SDS) 
(Sigma) supplemented with 1% protease inhibitor 
cocktail (Sigma). The cell pellet was resuspended in 
50–150 μL of the lysis solution and incubated for 
30 min on ice. Cell debris was separated from protein 
content by centrifugation at 13,000 × g for 10 min, 
after which the supernatant was transferred into 
a clean 1.5 mL tube. Extracted protein was measured 
using a Bicinchoninic Acid Protein Assay kit (Thermo 
Fisher, Waltham, MA, USA). 
Western blotting
Denatured protein samples were run (20 µg pro-
tein/sample) on 12% SDS-polyacrylamide gels (Bio-
Rad; 4561043EDU) and electro-transferred onto 
a polyvinylidene fluoride membrane (Thermo Fisher). 
The following primary antibodies were utilised to 
probe the membrane: rabbit anti-mouse (polyclonal 
antibody-middle region) PLS3 (PA5-27883) (Thermo 
Fisher, 1/500) and anti-mouse alpha-tubulin (Cal-
biochem, 1/1000). Secondary antibodies included 
goat anti-rabbit IgG H&L (HRP) (Abcam ab45769, 
1/1000). The membrane was developed using the 
enhanced chemiluminescence plus detection kit 
(Biological industries, 20-500-120), and signals were 
visualised using G-Box (Sygene) and ChemiImager 
software (Alpha Innotech). Alpha-tubulin was used 
as a loading control. The density of each band was 
integrated and the ratio of the densitometric values 
of each sample was obtained. Western blotting was 
performed in triplicate. Variation in protein expres-
sion was evaluated using ChemiImager software to 
compare samples and controls.
Immunocytochemistry
Immunofluorescence staining was performed on 
HEK293T and NSC-34 cells. Using a 6-well plate, at 
a density of 50,000 cells per well the cells were plated 
onto glass coverslips. Both cell lines were transduced 
with LV-PLS3. Five days after transduction, cells were 
washed with PBS and fixed in 4% paraformaldehyde 
in PBS (pH 7.3) for 15 min at 25°C. Thereafter, cells 
were washed with Dulbecco’s PBS and stored at 4°C 
until the staining procedure was performed. Cell mem-
branes were permeabilised by incubating the cells in 
blocking solution (0.3% Triton X-100 and 10% goat 
serum in PBS) for 2 h at 25°C. The blocking solution 
was removed and cells were incubated in anti-rabbit 
PLS3 (1:500; ab45769) overnight. The next day, follow-
ing three 10-min washes in PBS, cells were incubated 
in anti-rabbit IgG Alexa Fluor 568 secondary antibody 
for 1 h in the dark at 25°C. Finally, cells were washed 
10 min in PBS and mounted using Vectashield hard 
mounting medium on glass slides with 4’,6-diamidi-
no-2-phenylindole (DAPI; D9542 Sigma). Confocal im-
ages of selected fields were collected using a Leica SP5 
microscope system at 63 × magnification and were 
processed using Image J software. Approximately 
20 images were taken per slide; representative images 
are presented in Figures 1 and 2.
Cell viability assay and oxidative stress assessment
NSC-34 cells were plated in 96-well plates at 
a density of 20,000 cells/well. Plates contained NT cells 
and LV-LacZ-transduced (20 MOI) or LV-PLS3-trans-
duced (20 MOI) cells. Each condition comprised 
9 replicates. 
In order to induce oxidative stress, NSC-34 cells 
were deprived of serum for 6 h. To assess oxidative 
stress, dichlorodihydrofluorescein (DCF) dye (10 mM) 
(Thermo Fisher) was added to the NSC-34 cells at 
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Figure 1. A, B. Immunofluorescent validation of lentiviral vector (LV)-plastin 3 (PLS3) transduction in HEK293T cells. LV-PLS3 was introduced 
to HEK293T cells at multiplicity of infection (MOI) levels of either 20 or 40. Non-transduced cells were immunostained and served as a negative 
control. Nuclei are counterstained with DAPI (blue) and PLS3 is indicated in red. The white arrows indicate PLS3 expression in both the nucleoli 
and the cytoplasm. Scale bar; 100 μm (A) and 20 μm (B).
Figure 2. Lentiviral vector (LV)-mediated plastin 3 (PLS3) overexpression in NSC-34 cells assessed by immunofluorescence. NSC-34 cells were 
transduced with LV-PLS3 at various multiplicities of infection (MOIs, 5, 20, and 40). Non-transduced (NT) cells were included as negative controls. 
Nuclei are counterstained with DAPI (blue) and PLS3 is indicated in red. The scale bar (20 μm).
B
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a final concentration of 5 μM. An initial reading was 
acquired prior to the dye addition to account for 
background fluorescence. Oxidative stress was cal-
culated by monitoring DCF fluorescence acceleration 
(emission at 530 nm and excitation at 485 nm). Tox-
icity of the assay was checked through the addition 
of ethidium homodimer-1 (EthD-1) dye (Invitrogen), 
together with the DCF dye, at an absolute 0.33 μM 
concentration. Fluorescence was measured at an ex-
citation of 530 nm/emission 645 nm using a Sian 
programme on the fusion microplate reader (Perkin 
Elmer). LVs were added 1 h after serum withdrawal, 
at the beginning of the experiment. 
In order to analyse these experiments, the aver-
age blank fluorescence value was subtracted from 
each well for both DCF and EthD-1 data. Data was 
normalised by dividing DCF fluorescence by EthD-1 
fluorescence. Ten plates were assayed and statistical 
analysis was performed after normalising the results 
of each plate to the values obtained in NT cells.
Quantification of living cell numbers in the 96-well 
plates was performed using dilutions of 0.1 volumes 
reduction of 5 mg/mL MTT (Thermo Fisher) via cellular 
dehydrogenases. One dimethylformamide volume 
was added (DMF, SDS, 20% SDS in 50% DMF, pH 4.7) 
per well at 25°C and, after 1 h of incubation at 37°C, 
wells were placed on a shaking incubator for 1 h. 
Absorbance was assessed at 595 nm. 
Statistical analysis
Data were assessed using a one-way ANOVA and 
results are presented as the average measurements 
per plate ± standard deviation (SD).
Graph-Pad Prism software version 7.0 was used to 
analyse the data. A one-way ANOVA was utilised to 
compare the variance between untreated and treated 
cells. P < 0.05 was considered significantly different. 
RESULTS 
Lentiviral vectors mediate efficient 
overexpression of PLS3 in cell lines 
Human embryonic kidney (HEK293T) and NSC-34 
MN-like cells transduced with an LV carrying the PLS3 
gene (LV/PLS3) exhibited a significant rise in PLS3 
expression compared to NT control cells. 
PLS3 protein levels in HEK293T cells  
transduced with LV-PLS3
Transduction of HEK293T cells was performed 
using the LV-PLS3 vector at different multiplicities 
of infection (MOIs; 5, 20, and 40). The experiment 
was repeated three times (n = 3) and demonstrated 
that LV-PLS3 transduction successfully induced PLS3 
overexpression in HEK293T cells (Fig. 3). Western 
blot analysis (Fig 3A) revealed the appearance of 
a protein band (70-kDa), indicative of PLS3 in all 
three conditions. A 50-kDa band was detected using 
western immunoblotting for α-tubulin, which served 
as a loading control. In NT cells, endogenous PLS3 
expression was undetectable. Densitometry analysis 
of western blots revealed a correlation between in-
creased transgene PLS3 expression and the MOI of the 
LV used for transduction. PLS3 expression was max-
imum 5 days after transduction with MOI 20, show-
ing a 7-fold increase compared to NT cells (Fig. 3B). 
Moreover, a previous study reported no signs of tox-
icity or any apparent differences in cellular growth 
rate, even after transduction with higher MOIs (data 
not provided) [13]. 
Transduction efficiency of LV-PLS3 in HEK293T cells 
Immunofluorescence was performed to evaluate 
the expression and localisation of PLS3 in HEK293T 
cells 72 h after transduction with (LV-PLS3; MOIs 
Figure 3. Western blot validation of lentiviral vector (LV)-plastin 3 
(PLS3) transduction efficiency in HEK293T cells. A. Western blot of 
PLS3 protein expression in HEK293T cells transduced with LV-PLS3 
(5, 20, and 40) multiplicities of infection (MOIs). Non-transduced 
(NT) cells served as a negative control. WB membrane was probed 
with antibody against human PLS3. Alpha-tubulin served as loading 
control; B. Densitometry analysis of PLS3 levels in transduced cells 
with different LV-PLS3 MOIs (5, 20, and 40) normalised to NT cells. 
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5 and 20) compared to NT HEK293T cells (Fig. 1). 
The experiment was performed in triplicate (n = 3). 
The results summarised in Figure 1 indicate that ap-
proximately 80% of the LV-PLS3 transduced cells with 
MOI 20 overexpressed human PLS3. PLS3 localisation 
was observed in a granular staining pattern, cover-
ing an area within the cytoplasm and nucleus. This 
experiment confirmed that the LV-PLS3 vector was 
capable of mediating PLS3 gene delivery and expres-
sion in vitro. 
LV-PLS3 transduction efficiency in NSC-34 cells 
After verifying the functionality of LV-PLS3 in 
HEK293T cells, the same LV was used to transduce 
NSC-34 MN-like cells in order to investigate PLS3 ef-
fect in an in vitro SMA model. Immunofluorescence 
was first used to assess the expression of PLS3 5 days 
after transduction at different LV-PLS3 MOI levels (5, 
20, and 40) compared to non-transduced NSC-34 
cells. The experiment was repeated 3 times (n = 3). 
PLS3 localisation was observed throughout NSC-34 
cells and was associated with the cytoplasm and 
nucleus (Fig. 1). Interestingly, this staining pattern 
differed from that observed in HEK293T cells, which 
was granular in nature (Figs. 1, 2). This observation 
may be due to differences in cell type. This experiment 
confirmed functionality and efficacy of the LV-PLS3 
vector in expressing PLS3 in NSC-34 MN-like cells.
Oxidative stress measurement 
in PLS3-overexpressing NSC-34 cells 
In order to determine whether PLS3 overexpres-
sion reduced oxidative stress and thus protected cells 
against subsequent damage, NT cells and NSC-34 cells 
transduced to overexpress PLS3 or LacZ were cultured 
under serum-deprived conditions and subjected to 
the DCF assay. A separate set of NT control cells cul-
tured in serum (basal condition) were subjected to the 
same DCF assay. DCF is a lipophilic cell-permeant dye 
which, upon entering a cell, loses its acetate groups 
via intracellular esterases. This action renders the dye 
hydrophilic and thus unable to leave the cell, mak-
ing it suitable for measuring intracellular oxidative 
stress. Using this approach, serum-deprived NT cells 
exhibited significant increases in intracellular levels of 
oxidised DCF when compared to NT cells under basal 
conditions (p < 0.05; Fig. 4). This experiment also 
revealed that PLS3-overexpression in serum-deprived 
NSC-34 cells did not significantly reduce oxidative 
stress relative to LV-LacZ-transduced and NT cells 
grown under the same conditions. This demonstrates 
that PLS3 overexpression was not sufficient to protect 
NSC-34 MN-like cells against oxidative damage. 
Cell metabolic activity assay
After the DCF assay, a cell metabolic activity assay 
(3’-(4’,5’-dimethylthiazol-2-yl)-2’,5’-diphenyltetrazoli-
um bromide [MTT]) was performed on the same 
cultures in order to justify plating variability; data 
obtained by the MTT assay were normalised in ac-
cordance with the number of cells.
After oxidative stress induction, the durability 
of cells transduced with LV-PLS3 was observed to 
increase by approximately 92% (p < 0.001, n = 4) 
in comparison to NT cells and 61% (p < 0.01, n = 4) 
in comparison to LV-LacZ-transduced cells (Fig. 5). 
Figure 4. Oxidative stress levels in NSC-34 cells as assessed by 
a dichlorodihydrofluorescein assay after serum deprivation. Over-
expression of plastin 3 (PLS3) in NSC-34 cells (red bar) did not 
significantly decrease serum deprivation-induced oxidative stress 
when compared to lentiviral vector (LV-LacZ)-transduced (green bar) 
and non-transduced (NT) cells (yellow bar). No significant difference 
in oxidative stress was observed in NT cells under basal conditions 
(blue bar, data not provided). 
Figure 5. NSC-34 cell survival as determined by a cell metabolic activ-
ity assay. The 3’-(4’,5’-dimethylthiazol-2-yl)-2’,5’-diphenyltetrazolium 
bromide (MTT) assay was used to determined NSC-34 cell survival 
5 days post-transduction with lentiviral vector (LV)-plastin 3 (PLS3) 
or LV-LacZ (multiplicity of infection = 20) under basal conditions and 
after oxidative stress induction (two-way ANOVA, Bonferroni’s post-
hoc test, p < 0.05, n = 5, mean ± SEM); *p < 0.05; **p < 0.01; 
***p < 0.001.
7A.R. Alrafiah, Effect of an actin-binding protein in an in vitro model of motor neuron disease
Previous studies have confirmed that 6 h of menadi-
one administration in a redox cycling system is suf-
ficient to increase ROS within numerous subcellular 
chambers [20]. In this study, PLS3 overexpression in 
serum-deprived NSC-34 cells promoted cell surviva-
bility following menadione administration; however, 
the increase in viability was not significantly different 
when compared to serum-deprived NT cells. One 
possible explanation for the lack of significance is the 
elevated toxicity and cell loss (76%) observed in NT 
cells. As NSC-34 cells are specifically susceptible to 
oxidative stress, cell death likely occurred prior to the 
redeeming effect of PLS3 upregulation. Furthermore, 
delivering PLS3 under basal conditions resulted in 
a 68% increase in NSC-34 cell number (p < 0.001, 
n = 4) compared to that of NT cells. Likewise, LV-PLS3 
transduction under basal conditions increased NSC-34 
cell counts by 35% (p < 0.05, n = 4) in comparison 
to cells transduced with LV-LacZ, and further resulted 
in a greater growth ratio.
DISCUSSION
This study attempted to assess the potential PLS3 
anti-oxidative effect of in an in vitro SMA model. In 
order to do so, a lentivirus was used to confer stable 
PLS3 overexpression in NSC-34 cells. Oxidative stress 
was then induced by depriving cells of serum and 
the levels of intracellular oxidative mediators were 
assessed using a fluorimetric assay (DCF). LVs were 
selected as gene delivery vectors due to their ability 
to efficiently transfer genes to cells of the CNS in vitro 
and in vivo, and because they can transduce both 
dividing and non-dividing cells, including neurons 
[6]. In addition, it has been reported that LVs can effi-
ciently deliver genes to different primary neuron types 
across a broad range of species, including humans, 
resulting in long-term gene expression [8, 15]. Two 
cell lines were used (HEK293T and NSC-34) to assess 
LV transduction efficiency, and NSC-34 MN-like cells 
were further selected as an in vitro model of SMA. 
Ideally, SMA pathophysiology should be studied in in 
vitro cultures of primary MNs [10, 15, 18, 23]. However, 
due to decreased MN culture yields, the NSC-34 cell 
line is considered a suitable alternative to MN cultures 
and has been widely used to model MN diseases [13]. 
Indeed, NSC-34 MN-like cells differentiate via a process 
resembling that of primary MNs, comprise extended 
neurites, and express MN-specific markers [4].
The therapeutic potential of the PLS3 gene has 
previously been demonstrated using a tissue cul-
ture-based example of SMN1-associated SMA [7, 23]. 
While the findings of the current study are in agree-
ment with previous reports, this investigation re-
vealed that viral delivery of PLS3 did not protect 
NSC-34 cells against serum deprivation-induced ox-
idative stress. The distribution of PLS3 in astrocytes 
and other neural cells should be considered when 
investigating the therapeutic potential of virally de-
livered PLS3 to MNs. Our previous research on the 
differential expression patterns of PLS3 provided 
histological evidence that PLS3 immunoreactivity is 
present in the mouse cerebrum and spinal cord [4]. 
This supports the hypothesis that direct gene trans-
mission toward MNs may promote the development 
of protective strategies to counter oxidative stress. 
However, viral delivery of SMN into SMA pluripotent 
stem cell cultures (SMN-deficient) restored catalase 
levels to normal and reversed astrocyte activation, 
without changing the formation of the markers of 
the oxidative stress or the mitochondrial respiration. 
These results reveal that SMN insufficiency promotes 
the reactivity of astrocyte, but that this effect is not 
elicited via an oxidative stress-mediated process [25].
While several factors, including oxidative stress, 
contribute to various age-affiliated neurodegenera-
tive disorders, their involvement in the pathogenesis 
of SMA remains unclear. One potential interpretation 
for this variation is the age of onset for various age-
linked diseases, where oxidative stress could increase 
over time in order to alter neurons in a specific region. 
As SMA type I occurs in infancy, neurons are only 
exposed to stressful surroundings for a brief amount 
of time. Moreover, for the reduction of stress and 
cell loss, SMN-deficient cells may utilize endogenous 
mechanisms. 
In the current study, PLS3 overexpression did not 
significantly reduce oxidative stress, nor did it ob-
viously alter NSC-34 survival or morphology. These 
findings also reveal that other antioxidant genes 
associated with this pathway were unable to inde-
pendently induce neuroprotection. One explanation 
for the lack of effect is the possibility that cells were 
not sufficiently mature, prohibiting the ability to re-
duce oxidative stress under the current circumstances. 
Furthermore, the use of primary MN cultures, rather 
than the NSC-34 cell line, would be more appropriate 
to elucidate mechanisms underlying cell protection 
within SMA and other MN disorders. Nonetheless, 
NSC-34 cells continue to be fitting for studies on neu-
roprotection [22] and neurotoxins [21], and to explore 
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the outcomes of cerebrolysin [22]. As mentioned, 
NSC-34 cells display similar properties to MNs when 
exposed to conditions which promote maturation 
and differentiation [24]. Moreover, the NSC-34 cell 
line could be adopted to study the pathophysiological 
features of amyotrophic lateral sclerosis — another 
neurodegenerative MN disease. Thus, while this cell 
line was not ideal for the current study, it appears 
well-suited as a therapeutic screening tool and for 
specialised experiments.  
CONCLUSIONS
In this study, PLS3 overexpression in NSC-34 MN- 
-like cells did not readily reduce serum deprivation-in-
duced oxidative stress levels. These findings do not, 
however, exclude the possibility that PLS3 exerts an 
anti-oxidative effect that could not be detected using 
the current experimental setup. Future investigations 
using other experimental designs that include prima-
ry mouse MNs or human induced pluripotent stem 
cell-derived MNs from patients with SMA will be useful 
to determine the full neuroprotective efficacy of PLS3.
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